Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk
Open Access
- 24 February 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Molecular Cancer
- Vol. 20 (1), 1-5
- https://doi.org/10.1186/s12943-021-01336-4
Abstract
No abstract availableKeywords
Funding Information
- Foundation for the National Institutes of Health (R01EY026682, R01EY024665, R01EY025225, R01EY024698, R01EY03195201, and P30EY026877, F30EYE027986 and T32GM007337)
- Research to Prevent Blindness
- The Cancer League
This publication has 12 references indexed in Scilit:
- Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal MelanomaAmerican Journal of Ophthalmology, 2018
- MOLECULAR PROGNOSTICS FOR UVEAL MELANOMARetina, 2018
- Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanomaBritish Journal of Cancer, 2017
- Uveal MelanomaPublished by Springer Science and Business Media LLC ,2016
- PRAME as an Independent Biomarker for Metastasis in Uveal MelanomaClinical Cancer Research, 2016
- Fine-needle aspiration biopsy of uveal melanoma: outcomes and complicationsBritish Journal of Ophthalmology, 2015
- Collaborative Ocular Oncology Group Report Number 1: Prospective Validation of a Multi-Gene Prognostic Assay in Uveal MelanomaOphthalmology, 2012
- Uveal Melanoma: Trends in Incidence, Treatment, and SurvivalOphthalmology, 2011
- An Accurate, Clinically Feasible Multi-Gene Expression Assay for Predicting Metastasis in Uveal MelanomaThe Journal of Molecular Diagnostics, 2010
- Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF).1998